Expression of LDH and CEA in serum in the process of targeted therapy of lung adenocarcinoma and the association between them and prognosis.

Expression of lactate dehydrogenase (LDH) and carcinoembryonic antigen (CEA) in serum was investigated in the process of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeting for treating lung adenocarcinoma and the association between LDH, CEA and prognosis of patients was evaluated. A retrospective analysis of 89 patients with lung adenocarcinoma admitted to The First People's Hospital of Chuzhou from January 2014 to February 2015 was performed. Fifty-one patients who received resection were considered the operation group, while the other 38 patients received EGFR-TKI targeted therapy and were considered the targeted group. Electrochemiluminescence and automatic biochemical analyzer were respectively used to detect the expression of CEA and LDH in serum. The therapeutic effective rates and the expression levels of LDH and CEA of the patients were compared. The patients in the targeted group were divided into LDH high-expression group, LDH low-expression group, CEA high-expression group and CEA low-expression group according to the median of the expression levels of LDH and CEA. The therapeutic effective rate in LDH high-expression group (65.00%) was significantly lower than that in LDH low-expression group (100.00%) (P=0.004). The therapeutic effective rate in CEA high-expression group (64.71%) was significantly lower than that in CEA low-expression group (95.24%) (P=0.016). The 3-year overall mortality rate in LDH high-expression group (47.37%) was significantly higher than that in LDH low-expression group (11.11%) (P=0.034). The 3-year overall mortality rate in CEA high-expression group (56.25%) was significantly higher than that in CEA low-expression group (4.76%) (P=0.020). The levels of CEA and LDH in serum were abnormally expressed in the process of the treatment of lung adenocarcinoma targeted by EGFR-TKI, which had great significance for monitoring the efficacy and prognosis of the treatment of lung adenocarcinoma targeted by EGFR-TKI.